AstraZeneca PLC AZNCF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AZNCF is a good fit for your portfolio.
News
-
AstraZeneca withdraws COVID-19 vaccine
-
Astrazeneca on Track for Record High Close — Data Talk
-
Astrazeneca on Track for Record High Close — Data Talk
-
Astrazeneca Up Nearly 6%, on Pace for Largest Percent Increase Since November 2022 — Data Talk
-
AstraZeneca Earnings, Sales Rise, Beating Forecasts — Update
-
AstraZeneca Earnings, Sales Rise, Beat Forecasts
-
AstraZeneca Executives' Compensation Policy Passes With Low Shareholder Approval
-
AstraZeneca Raises Dividend
Trading Information
- Previous Close Price
- $152.40
- Day Range
- $147.65–147.65
- 52-Week Range
- $118.16–159.12
- Bid/Ask
- $147.65 / $159.35
- Market Cap
- $228.89 Bil
- Volume/Avg
- 106 / 3,273
Key Statistics
- Price/Earnings (Normalized)
- 19.84
- Price/Sales
- 4.81
- Dividend Yield (Trailing)
- 1.88%
- Dividend Yield (Forward)
- 1.88%
- Total Yield
- 1.88%
Company Profile
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Growth
- Total Number of Employees
- 89,900
- Website
- https://www.astrazeneca.com
Competitors
Valuation
|
Metric
|
AZNCF
|
LLY
|
MRK
|
|---|---|---|---|
Price/Earnings (Normalized) | 19.84 | 83.18 | 59.70 |
Price/Book Value | 6.07 | 57.69 | 8.13 |
Price/Sales | 4.81 | 19.55 | 5.37 |
Price/Cash Flow | 22.69 | 81.27 | 18.89 |
Price/Earnings
AZNCF
LLY
MRK
Financial Strength
|
Metric
|
AZNCF
|
LLY
|
MRK
|
|---|---|---|---|
Quick Ratio | 0.70 | 0.68 | 0.68 |
Current Ratio | 0.89 | 1.35 | 1.25 |
Interest Coverage | 5.32 | 14.11 | 3.97 |
Quick Ratio
AZNCF
LLY
MRK
Profitability
|
Metric
|
AZNCF
|
LLY
|
MRK
|
|---|---|---|---|
Return on Assets (Normalized) | 59.78% | 11.20% | 5.22% |
Return on Equity (Normalized) | 157.53% | 57.69% | 13.56% |
Return on Invested Capital (Normalized) | 88.21% | 20.65% | 8.29% |
Return on Assets
AZNCF
LLY
MRK
Drug Manufacturers - General Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
LLY
| Eli Lilly and Co | Zbkmchmqd | Vypy | $736.6 Bil | |
JNJ
| Johnson & Johnson | Mgfxkzvlx | Yddd | $357.9 Bil | |
MRK
| Merck & Co Inc | Wjnzgrpc | Mjlhg | $330.2 Bil | |
ABBV
| AbbVie Inc | Jnzjgvl | Lmfw | $283.3 Bil | |
AZN
| AstraZeneca PLC ADR | Wyxhwmpph | Tgzjb | $237.7 Bil | |
NVS
| Novartis AG ADR | Jcbcxgmr | Sbgz | $202.0 Bil | |
RHHBY
| Roche Holding AG ADR | Mzhswwnx | Njx | $196.9 Bil | |
AMGN
| Amgen Inc | Xnskddkwz | Ndwb | $161.1 Bil | |
PFE
| Pfizer Inc | Hzkwlxxyr | Lvgfh | $160.2 Bil | |
SNY
| Sanofi SA ADR | Hhcgnllnq | Cdlw | $125.0 Bil |